PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.539
https://www.valueinhealthjournal.com/article/S1098-3015(19)32917-1/fulltext
Section Title :
Section Order :
10460
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32917-1&doi=10.1016/j.jval.2019.09.539